Jonathan Piazza
Equibles does not estimate personal net worth.
About Jonathan Piazza
Earlier roles on record: CFO at ARS Pharmaceuticals, Inc. (SPRY) until September 2, 2022. ARS Pharmaceuticals, Inc. reported in an 8-K filed September 2, 2022 that Jonathan Piazza was terminated as Chief Financial Officer, effective September 2, 2022.
“On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. ("Silverback") approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022 (the "Transition Date")”
Affiliation history
-
Start not stated–2022-09-02